The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...
Johnson & Johnson is suing the federal government over its rebuke of the company’s alternative model for 340B ...
Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...
Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...
A lot of Amgen's future rides on its experimental obesity medicine MariTide. At least in the minds of investors. Ahead of the ...
Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...
AstraZeneca CEO Pascal Soriot affirms commitment to China despite investigation involving China president Leon Wang and other employees. Wang, who reported directly to Soriot, and former AstraZeneca ...
Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...
Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...
Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback